PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside

Arafeh, 2019, PIK3CA in cancer: the past 30 years, Semin. Cancer Biol., 18

Murugan, 2013, Genetic deregulation of the PIK3CA oncogene in oral cancer, Cancer Lett., 338, 193, 10.1016/j.canlet.2013.04.005

Leslie, 2012, PTEN: an intercellular peacekeeper?, Sci. Signal., 5, e50, 10.1126/scisignal.2003685

Mundi, 2016, AKT in cancer: new molecular insights and advances in drug development, Br. J. Clin. Pharmacol., 82, 943, 10.1111/bcp.13021

Miller, 2011, Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer, J. Clin. Oncol., 29, 4452, 10.1200/JCO.2010.34.4879

Xie, 2016, mTOR inhibitors in cancer therapy, F1000Res, 5, 10.12688/f1000research.9207.1

Lemmon, 2010, Cell signaling by receptor tyrosine kinases, Cell, 141, 1117, 10.1016/j.cell.2010.06.011

Fedele, 2010, Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers, Proc. Natl. Acad. Sci. U. S. A., 107, 22231, 10.1073/pnas.1015245107

Zhao, 2008, Class I PI3K in oncogenic cellular transformation, Oncogene, 27, 5486, 10.1038/onc.2008.244

Hao, 2016, Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer, Nat. Commun., 7, 11971, 10.1038/ncomms11971

Lee, 2015, PI3K/Akt/mTOR inhibitors in breast cancer, Cancer Biol. Med., 12, 342

Vanhaesebroeck, 2010, The emerging mechanisms of isoform-specific PI3K signalling, Nat. Rev. Mol. Cell Biol., 11, 329, 10.1038/nrm2882

Bonneau, 2000, Mutations of the human PTEN gene, Hum. Mutat., 16, 109, 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0

Álvarez-Garcia, 2019, Mechanisms of PTEN loss in cancer: it’s all about diversity, Semin. Cancer Biol., 18

Cornu, 2013, mTOR in aging, metabolism, and cancer, Curr. Opin. Genet. Dev., 23, 53, 10.1016/j.gde.2012.12.005

Jacinto, 2004, Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive, Nat. Cell Biol., 6, 1122, 10.1038/ncb1183

Murugan, 2013, Mutations in critical domains confer the human mTOR gene strong tumorigenicity, J. Biol. Chem., 288, 6511, 10.1074/jbc.M112.399485

Waldner, 2016, New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation, Br. J. Clin. Pharmacol., 82, 1158, 10.1111/bcp.12893

Porta, 2014, Targeting PI3K/Akt/mTOR signaling in cancer, Front. Oncol., 4, 64, 10.3389/fonc.2014.00064

Courtney, 2010, The PI3K pathway as drug target in human cancer, J. Clin. Oncol., 28, 1075, 10.1200/JCO.2009.25.3641

Janku, 2017, Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: from laboratory to patients, Cancer Treat. Rev., 59, 93, 10.1016/j.ctrv.2017.07.005

Greenwell, 2017, PI3K inhibitors: understanding toxicity mechanisms and management, Oncology (Williston Park), 31, 821

Gojo, 2013, Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome, Invest. New Drugs, 31, 1217, 10.1007/s10637-013-9937-8

Pons-Tostivint, 2017, Targeting PI3K signaling in combination cancer therapy, Trends Cancer, 3, 454, 10.1016/j.trecan.2017.04.002

Fruman, 2014, PI3K and cancer: lessons, challenges and opportunities, Nat. Rev. Drug Discov., 13, 140, 10.1038/nrd4204

Boucher, 2014, Insulin receptor signaling in normal and insulin-resistant states, Cold Spring Harb. Perspect. Biol., 6, 10.1101/cshperspect.a009191

Juric, 2015, Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor, Nature, 518, 240, 10.1038/nature13948

Bellacosa, 2005, Activation of AKT kinases in cancer: implications for therapeutic targeting, Adv. Cancer Res., 94, 29, 10.1016/S0065-230X(05)94002-5

West, 2002, Activation of the PI3K/Akt pathway and chemotherapeutic resistance, Drug Resist. Update, 5, 234, 10.1016/S1368-7646(02)00120-6

Arcaro, 2007, The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications, Curr. Genomics, 8, 271, 10.2174/138920207782446160

Ogawara, 2002, Akt enhances Mdm2-mediated ubiquitination and degradation of p53, J. Biol. Chem., 277, 21843, 10.1074/jbc.M109745200

Nitulescu, 2016, Akt inhibitors in cancer treatment: the long journey from drug discovery to clinical use (Review), Int. J. Oncol., 48, 869, 10.3892/ijo.2015.3306

Chumsri, 2011, Aromatase, aromatase inhibitors, and breast cancer, J. Steroid Biochem. Mol. Biol., 125, 13, 10.1016/j.jsbmb.2011.02.001

Banerji, 2018, A phase I open-label study to identify a dosing regimen of the Pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers, Clin. Cancer Res., 24, 2050, 10.1158/1078-0432.CCR-17-2260

Altomare, 2010, GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt, Clin. Cancer Res., 16, 486, 10.1158/1078-0432.CCR-09-1026

Aghajanian, 2018, A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors, Invest. New Drugs, 36, 1016, 10.1007/s10637-018-0591-z

de Bono, 2019, Randomized phase II study evaluating akt blockade with ipatasertib, in combination with Abiraterone, in patients with metastatic prostate cancer with and without PTEN loss, Clin. Cancer Res., 25, 928, 10.1158/1078-0432.CCR-18-0981

Ma, 2017, A phase II trial of neoadjuvant MK-2206, an AKT inhibitor, with anastrozole in clinical stage II or III PIK3CA-mutant ER-positive and HER2-negative breast cancer, Clin. Cancer Res., 23, 6823, 10.1158/1078-0432.CCR-17-1260

Carnero, 2010, The PKB/AKT pathway in cancer, Curr. Pharm. Des., 16, 34, 10.2174/138161210789941865

Manning, 2017, AKT/PKB signaling: navigating the network, Cell, 169, 381, 10.1016/j.cell.2017.04.001

Dienstmann, 2014, Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors, Mol. Cancer Ther., 13, 1021, 10.1158/1535-7163.MCT-13-0639

Jansen, 2016, Is there a future for AKT inhibitors in the treatment of cancer?, Clin. Cancer Res., 22, 2599, 10.1158/1078-0432.CCR-16-0100

Ma, 2016, A phase I study of the AKT inhibitor MK-2206 in combination with hormonal therapy in postmenopausal women with estrogen receptor positive metastatic breast cancer, Clin. Cancer Res., 22, 2650, 10.1158/1078-0432.CCR-15-2160

Miller, 2010, Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer, J. Clin. Invest., 120, 2406, 10.1172/JCI41680

Bachelot, 2012, Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study, J. Clin. Oncol., 30, 2718, 10.1200/JCO.2011.39.0708

Thorpe, 2015, PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting, Nat. Rev. Cancer, 15, 7, 10.1038/nrc3860

Vivanco, 2014, A kinase-independent function of AKT promotes cancer cell survival, Elife, 3

Wu, 2010, Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition, PLoS One, 5

Parikh, 2012, Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers, Proc. Natl. Acad. Sci. U. S. A., 109, 19368, 10.1073/pnas.1204384109

Fox, 2013, Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation, Breast Cancer Res., 15, R55, 10.1186/bcr3449

Laplanate, 2012, mTOR signaling in growth control and disease, Cell, 149, 274, 10.1016/j.cell.2012.03.017

Mortensen, 2015, CC-223, a potent and selective inhibitor of mTOR kinase: in vitro and in vivo characterization, Mol. Cancer Ther., 14, 1295, 10.1158/1535-7163.MCT-14-1052

Pei, 2012, Discovery and biological profiling of potent and selective mTOR inhibitor GDC-0349, ACS Med. Chem. Lett., 4, 103, 10.1021/ml3003132

Bhagwat, 2011, Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin, Mol. Cancer Ther., 10, 1394, 10.1158/1535-7163.MCT-10-1099

Moore, 2018, Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours, ESMO Open, 3, 10.1136/esmoopen-2017-000291

Abu-Khalaf, 2015, Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors, Cancer, 121, 1817, 10.1002/cncr.29254

Liu, 2019, Rapamycin: a bacteria-derived immunosuppressant that has anti-atherosclerotic effects and its clinical application, Front. Pharmacol., 9, 1520, 10.3389/fphar.2018.01520

Li, 2014, Rapamycin: one drug, many effects, Cell Metab., 19, 373, 10.1016/j.cmet.2014.01.001

Murugan, 2019, Identification and characterization of two novel oncogenic mTOR mutations, Oncogene, 26

Kwiatkowski, 2016, Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma, Clin. Cancer Res., 22, 2445, 10.1158/1078-0432.CCR-15-2631

Wagle, 2014, Response and acquired resistance to everolimus in anaplastic thyroid cancer, N. Engl. J. Med., 371, 1426, 10.1056/NEJMoa1403352

Murugan, 2015, Absence of somatic mutations of the mTOR gene in differentiated thyroid cancer, Meta Gene, 6, 69, 10.1016/j.mgene.2015.08.005

Hassan, 2014, Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors, Oncotarget, 5, 8544, 10.18632/oncotarget.2337

Morgan, 2018, Engineering CAR-T cells for improved function against solid tumors, Front. Immunol., 29, 2493, 10.3389/fimmu.2018.02493

Yap, 2011, First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors, J. Clin. Oncol., 29, 4688, 10.1200/JCO.2011.35.5263

Molife, 2014, Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors, J. Hematol. Oncol., 3, 1, 10.1186/1756-8722-7-1

Crouthamel, 2009, Mechanism and management of AKT inhibitor-induced hyperglycemia, Clin. Cancer Res., 15, 217, 10.1158/1078-0432.CCR-08-1253

De Santis, 2019, Targeting PI3K signaling in cancer: challenges and advances, Biochim. Biophys. Acta Rev. Cancer, 1871, 361, 10.1016/j.bbcan.2019.03.003

Esposito, 2019, Safety, tolerability, and management of toxic effects of phosphatidylinositol 3-kinase inhibitor treatment in patients with cancer: a review, JAMA Oncol., 28